Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01983410 · ClinicalTrials.gov registry record
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
A clinical trial of Pancreatic Ductal Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 600
- Enrollment target
- 13
- Study locations
NCT01983410: Active study of Pancreatic Ductal Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01983410 is a study of Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 600 participants, roughly in line with the 594-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target. The trial reports 13 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01983410, a study of Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.
Primary Outcome
Establishment of a BRCA mutation carriers PDAC Registry with appropriate control groups, and collection and storage of biological material for future studies.
Conditions Studied
Interventions
- BEHAVIORAL The risk assessment questionnaire
- OTHER Blood specimens
- OTHER tumor tissue samples will be requested
Study Locations (13)
New York
- Cold Springs Harbor Laboratory (Specimen Analysis) - Cold Spring Harbor
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical College (Specimen Analysis) - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Other
- Shaare Zedek Medical Center - Jerusalem
- Weizmann Institute of Science (Specimen Analysis) - Rehovot
- Sheba Medical Center - Tel Litwinsky
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2013-11-04 |
| Est. Completion | 2026-11 |
What the registry record for NCT01983410 still lists
NCT01983410 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 594-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which The risk assessment questionnaire is the first listed.
NCT01983410 lists 13 locations in 4 states (New York, New Jersey, Other).
Frequently Asked Questions
What is clinical trial NCT01983410 about?
NCT01983410 is a clinical study titled "A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma". The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Ad...
What is the current status of trial NCT01983410?
This trial is currently active not recruiting. The enrollment target is 600 participants. The study started on 2013-11-04. Estimated completion is 2026-11.
What conditions does trial NCT01983410 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT01983410?
The interventions under investigation include: The risk assessment questionnaire (BEHAVIORAL), Blood specimens (OTHER), tumor tissue samples will be requested (OTHER).
Who is sponsoring clinical trial NCT01983410?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01983410 being conducted?
This trial has 13 study locations across New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01983410's enrollment target sits among peer trials
600 11th of 84 higher than 73 of 84 other Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI